It's still an expense though, so I disagree. NPAT is incredibly important IMHO and more important than EBIT.
Horses for courses, but NPAT is still the real bottom line for me.
So NPAT "linear" at best, but it was still negative IMO.
There is also competitor snapping at heels which is in FDA process. Disc Medicine, BEACON. Look it up.
It's still an expense though, so I disagree. NPAT is incredibly...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.37 |
Change
0.130(0.85%) |
Mkt cap ! $770.0M | |||
| Open | High | Low | Value | Volume |
| $15.36 | $15.54 | $15.18 | $1.274M | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $15.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 282 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |